Table 1.
Commercially available SARS-CoV-2 antibody assays.
| Assay | Type | ELISA Target | Use of DBS sample |
|---|---|---|---|
| Abbott Architect | Automated analyser | Nucleocapsid protein (NCP) IgG target | Currently not approved by manufacturer |
| Diasorin Liaison XL | Automated analyser |
Spike protein (Spike) IgG target. | Currently not approved by manufacturer |
| Euroimmun – NCP IgG | Manual ELISA |
NCP IgG target | Approved by manufacturer as a screening assay. DBS elution buffer and elution method described in IFU. Incubation steps require use of 37C incubator. |
| Euroimmun - Spike IgG | Manual ELISA |
Spike IgG target | Approved as confirmation assay post NCP reactive result. DBS elution buffer and elution method described in IFU. Incubation steps 37C. |
| Euroimmun - Spike IgA | Manual ELISA |
Spike IgA target | Approved as a supplemental assay. DBS elution buffer and elution method described in IFU. Incubation steps 37C. |
| Binding site – Spike total antibody | Manual ELISA |
Spike IgG/A/M | Approved by manufacturer. Elution buffer and method not described in IFU. Standardised in-house elution buffer and elution method used. Incubation steps at room temperature. |
| Wantai total antibody | Manual ELISA |
Spike receptor binding domain (RBD) total antibody | Not approved by manufacturer. Standardised in-house elution buffer and elution method used. Incubation steps 37C. Assay input volume 100µL serum. |